ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.

SAGE Sage Therapeutics Inc

13.71
0.605 (4.62%)
04 May 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type
Sage Therapeutics Inc NASDAQ:SAGE NASDAQ Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.605 4.62% 13.71 13.70 14.41 13.97 13.45 13.46 895,697 01:00:00

Sage Therapeutics to Present at 2019 Wedbush PacGrow Healthcare Conference

05/08/2019 9:30pm

Business Wire


Sage Therapeutics (NASDAQ:SAGE)
Historical Stock Chart


From May 2019 to May 2024

Click Here for more Sage Therapeutics Charts.

Sage Therapeutics (NASDAQ:SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating disorders of the brain, today announced that the Company will participate in the 2019 Wedbush PacGrow Healthcare Conference on Tuesday, August 13, 2019, in New York, NY.

Steve Kanes, M.D., chief medical officer of Sage, will be a featured speaker on the panel, Overcoming Challenges in CNS Drug Development, at 11:30 a.m. EDT.

A live webcast of the panel can be accessed on the investor page of Sage's website at investor.sagerx.com. A replay of the webcast will also be archived for up to 30 days on Sage's website following the conference.

About Sage Therapeutics Sage Therapeutics is a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating disorders of the brain. We are pursuing new pathways with the goal of improving brain health and our depression, neurology and neuropsychiatry franchise programs aim to change how brain disorders are thought about and treated. Our mission is to make medicines that matter so people can get better, sooner. For more information, please visit www.sagerx.com.

Investor Contact Maren Killackey 617-949-4113 maren.killackey@sagerx.com

Media Contact Alexis Smith 617-588-3740 alexis.smith@sagerx.com

1 Year Sage Therapeutics Chart

1 Year Sage Therapeutics Chart

1 Month Sage Therapeutics Chart

1 Month Sage Therapeutics Chart

Your Recent History

Delayed Upgrade Clock